Bevacizumab for recurrent ependymoma

Neurology

Volumn 73, Issue 20, 2009, Pages 1677-1680

  Green, R M ^a   Cloughesy, T F ^b   Stupp, R ^c   Deangelis, L M ^d   Woyshner, E A ^a   Ney, D E ^d,e   Lassman, A B ^d  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; IRINOTECAN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EPENDYMOMA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 73449145101     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c1df34     Document Type: Article

References (10)

1. CBTRUS. Central Brain Tumor Registry of the United States 2008 statistical report: primary brain tumors in the United States. Available at: http://www.cbtrus.org/. Accessed August 10, 2009.
2. Brandes AA, Cavallo G, Reni M, et al. A multicenter retrospective study of chemotherapy for recurrent intracra-nial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer 2005;104: 143-148.
3. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinote-can at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
4. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent gli-oblastoma. J Clin Oncol 2009;27:4733-4740.
5. Preusser M, Wolfsberger S, Haberler C, et al. Vascularization and expression of hypoxia-related tissue factors in in-tracranial ependymoma and their impact on patient survival. Acta Neuropathol 2005;109:211-216.
6. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for gli-oblastoma. N Engl J Med 2005;352:987-996.
8. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 2007;110:1542-1550.
9. Soffietti R, Costanza A, Laguzzi E, Trevisan E, Rudà R. Temozolomide in rare brain tumors of the adult: a prospective study: ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S, June 1 suppl):1574. Abstract.
10. Merchant TE, Li C, Xiong X, Gaber MW. Cytokine and growth factor responses after radiotherapy for localized ependymoma. Int J Radiat Oncol Biol Phys 2009;74:159-167.